🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million new cases per year. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, the spread of superbugs and the extremely scarce available drugs at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to major issues, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Data and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug successfully treated the vast majority of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The research enrolled over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Doctors treating patients have voiced optimism. Access to a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.